LONDON, May 14, 2020 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces its newly launched OR3O Dual Mobility System for total hip arthroplasty (THA) has received encouraging results from early surgeon experience. Utilizing proprietary OXINIUM™ DH Technology, the OR3O system offers the benefits of dual mobility – increased range of motion and “jump distance”1* – while also incorporating unique material advantages.
“The OR3O Dual Mobility System allows me to address multiple patient types, as I have implanted the system in the hypermobile primary all the way to complex revisions. Compared to other designs, the liner is easier to seat and lock inside the shell. The instruments and trials allow for a simple procedure. I could not be more satisfied with my clinical experience,” said Dr. Stephen Duncan at The University of Kentucky.
While current systems offer modular, dual mobility options with cobalt chrome liners, the OR3O Dual Mobility System utilizes Smith+Nephew’s latest advanced bearing surface, OXINIUM DH (Diffusion Hardened), for its liner, as well as an OXINIUM femoral head and highly cross-linked polyethylene (XLPE) insert. Hip implants made with OXINIUM Technology have shown reduced wear profiles and minimized corrosion when compared to hip implants made from cobalt chrome.2
“I am excited about what the OR3O Dual Mobility System can offer my patients as part of the hip care continuum. The system is uniquely set apart by offering OXINIUM DH Technology in a dual-bearing construct, and so far early case outcomes have been great,” said Dr. Edwin Su at The Hospital for Special Surgery in New York, NY.
Dual mobility solutions for the hip have been in clinical use for decades;3,4 however, a modular design that allows for internal screw fixation in the shell was introduced in 2010. Since its introduction, this segment continues to grow and is used to treat indications across the total hip spectrum from primary total hips all the way to complex revisions.
“The successful introduction of the OR3O Dual Mobility System into this growing category is a significant win for Smith+Nephew,” said Skip Kiil, President of Orthopaedics at Smith+Nephew. “Introducing an OXINIUM DH liner option and offering OXINIUM with XLPE throughout the entire size range sets our portfolio apart from the competition.”
Smith+Nephew’s OR3O Dual Mobility System is available in the United States for both primary and revision applications and offers cross-compatibility with the R3™ and REDAPT™ acetabular systems.
Invitation to Smith+Nephew Virtual Experience
OR3O will be showcased at Smith+Nephew’s virtual experience. Replacing cancelled in-person trade shows and training events such as the AAOS Annual Meeting, customers can explore an interactive, virtual view of Smith+Nephew technology, innovation and new products across Orthopaedics, Robotics, Sports Medicine, Wound and ASC virtual display areas and download specific content about products and techniques of interest.
*The jumping distance (JD) is the degree of lateral translation of the femoral head center required before dislocation occurs
- Sariali E, Lazennec JY, Khiami F & Catonné Y. Mathematical evaluation of jumping distance in total hip arthroplasty, Acta Orthopaedica. 2009;80(3): 277-282.
- Parikh A; Pawar V; Sprague J. Long-term Simulator Wear Performance of an Advanced Bearing Technology for THA. Poster Presented at ORS. 2013; Poster No:1028.
- Hampton C; Weitzler L; Baral E; Wright TM; Bostrom MPG. Do oxidized zirconium heads decrease tribocorrosion in total hip arthroplasty. Bone Joint J. 2019; 101-B: pp.386–389.
- Boyer, B; Philippot, R; Geringer J; Farizon F. Primary total hip arthroplasty with dual mobility socket to prevent dislocation: a 22-year follow-up of 240 hips. International Orthopaedics (SICOT), 36, 2012, 511-518.
- Reina, N; Pereek, A; Krych, AJ; Pagnano, MW; Berry, DJ; Abdel MP. Dual-Mobility Constructs in Primary and Revision Total Hip Arthroplasty: A Systematic Review of Comparative Studies. The Journal of Arthroplasty, 34, 2019, 594-603.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.